Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. develops healthcare technology for chronic low back pain through Nociscan, a cloud-based SaaS platform that uses magnetic resonance spectroscopy, biomarkers, signal processing and augmented intelligence algorithms to help physicians evaluate painful and nonpainful lumbar discs.
Company news commonly covers Nociscan adoption, clinical-site additions, commercial agreements with spine practices and academic medical centers, reimbursement activity, intellectual-property updates for AI-enabled workflows, and operating results. Updates also include capital actions and governance items tied to Aclarion’s Nasdaq-listed common stock and warrants.
Aclarion (Nasdaq: ACON) announced first patient enrollments at two additional CLARITY trial sites (Northwestern Medicine and Scripps Health), bringing the number of sites that completed regulatory setup to seven and sites that have enrolled patients to four.
The multi-site pivotal CLARITY trial will randomize up to 300 patients to evaluate Nociscan-guided surgical planning versus blinded care. The company expects an initial interim readout after the first cohort reaches a 3-month follow-up, projected in 3Q 2026, and aims to enroll ~25% of patients by end of Q2 2026. Full enrollment target is mid-2027, with possible early termination if significance is reached earlier.
Aclarion (Nasdaq: ACON) announced publication of a featured Tech Update on its Nociscan solution in the Special Pain Issue of the International Journal of Spine Surgery (IJSS) on Dec 4, 2025. The article highlights a clinical case where a 27-year-old with chronic low back pain had MRI-suspected L4/5 and L5/S1 pathology; a four-level Nociscan exam detected biomarkers at L5/S1 only, guiding the surgeon to perform a single-level artificial disc replacement at L5/S1 that eliminated the patient’s pain and restored activity. The release emphasizes Nociscan as a noninvasive, evidence-supported SaaS platform for distinguishing painful versus nonpainful lumbar discs and notes IJSS’s role in disseminating spine care innovations to an international audience.
Aclarion (NASDAQ: ACON) announced the appointment of Jason Brosniak as Commercial Director, Eastern U.S., effective Dec 2, 2025.
Brosniak brings 20+ years in commercial roles at MedTech firms including Relievant Medsystems, Kyphon, and Intrinsic Therapeutics and will lead adoption and payer engagement for Nociscan across the densely populated Eastern U.S. The hire follows recent UK commercial expansion and coincides with growing demand from real-world evidence trials and the national CLARITY randomized controlled trial.
Nociscan is described as a SaaS platform that noninvasively quantifies chemical biomarkers to help distinguish painful versus nonpainful lumbar discs.
Aclarion (Nasdaq: ACON, ACONW) appointed Dan Isherwood as UK Commercial Director to accelerate adoption of its Nociscan solution in the UK market.
The company said Nociscan is now reimbursed by three of the top four UK private insurers, covering more than 5.2 million lives, and has early integration at a leading London spine clinic. Isherwood brings imaging and spine commercial experience from J&J MedTech, EOS Imaging, and NuVasive and earlier NHS clinical experience.
Aclarion (Nasdaq: ACON) was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH on October 22, 2025.
The award, chosen from more than 1,800 submissions, recognizes Aclarion's Nociscan SaaS platform, which uses MR spectroscopy and proprietary AI to generate objective biomarkers to help physicians distinguish painful from non-painful lumbar discs. The company said the technology aims to improve personalized treatment decisions for chronic low back pain, a condition affecting an estimated 266 million people worldwide.
Aclarion (Nasdaq: ACON) issued a Q3 2025 corporate update highlighting accelerating commercial adoption, a strong cash position, and progress in its pivotal CLARITY trial.
Key facts: Nociscan scan volumes +89% YoY in Q3 with three consecutive record quarters; debt-free balance sheet with $13.3 million cash (≈$15.11/share) as of Oct 14, 2025; CLARITY enrolling with first patients at University of Miami and full enrollment targeted by Q4 2026; early 3-month interim readouts expected Q2 2026. Company appointed Greg Gould as CFO and will present at LD Micro on Oct 20, 2025.
Aclarion (Nasdaq: ACON) participated in the International Society of Pain and Neuroscience Annual Meeting in London on Oct 13, 2025, where a session co‑moderated by Doug Beall, M.D., highlighted the role of MR Spectroscopy and Aclarion’s Nociscan in identifying biomarkers of discogenic low back pain.
Nociscan is described as a SaaS platform that converts MR spectroscopy signals into objective biomarkers to help differentiate painful vs non‑painful lumbar discs and inform personalized treatment decisions. The company emphasized multidisciplinary clinical engagement and insurer approval at a UK clinic for study access.
Aclarion (NASDAQ: ACON / ACONW) will present at LD Micro Main Event XIX on Monday, October 20, 2025 at 12:00 PM PT at the Hotel del Coronado in San Diego.
Executive Chairman Jeff Thramann and CEO Brent Ness will speak about Aclarion's healthcare technology that uses biomarkers and proprietary augmented intelligence to help physicians identify the location of chronic low back pain. A virtual webcast registration is available.
Aclarion (Nasdaq: ACON) was named a finalist on Oct 7, 2025 for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH in the Rising Star - Clinical Diagnostic Device category.
Nociscan is described as a SaaS platform that transforms MR spectroscopy signals into objective biomarkers to noninvasively distinguish painful from non-painful lumbar discs, supporting more personalized treatment plans. The company cites an estimated 266 million people worldwide living with chronic low back pain and notes it was selected from more than 1,800 submissions.
Aclarion (NASDAQ:ACON) presented at LSI Europe '25, showcasing its Nociscan platform that combines MR spectroscopy with AI to identify chronic low back pain sources. The technology helps physicians differentiate between painful and non-painful lumbar discs, enabling more targeted treatment plans.
The company highlighted its ongoing 300-patient CLARITY randomized clinical trial, which aims to demonstrate improved surgical outcomes beyond the current 54% industry success rate. Interim results are expected in Q2 2026. The company also noted its strengthened balance sheet position to support commercial and clinical initiatives.